Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

Datopotamab Deruxtecan for Patients With Previous Treated HR-Positive, HER2-Negative Breast Cancer

Jane Meisel, MD

 

Jane Meisel, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, discussed results from the I-SPY 2.2 trial which investigated the clinical activity of datopotamab deruxtecan among patients with HR-positive, HER2-negative breast cancer. 


Source: 

Meisel J. Rates of pathologic complete response (pCR) after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY 2.2 trial. Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract LBA509 

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

Advertisement